ArticleTherapeutic advances in psychopharmacology2025
Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: a mirror-image study.
Article in Therapeutic advances in psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An exploratory study on the impact of medication usage patterns on relapse among community schizophrenia patients.BMC psychiatry · 2026Article
- Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview.Indian journal of psychiatry · 2026Article
- Clinical Practice Recommendations for Switching from Once-Monthly to Longer-Interval Paliperidone Palmitate Injectable in Schizophrenia Patients: A Modified Delphi Study in China.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-acting injectable (LAI) antipsychotics can improve treatment adherence in patients with schizophrenia. Despite their benefits, LAIs are underused in China compared to other countries. Little real-world evidence describes the impact of switching from oral to LAI antipsychotics on adherence and healthcare utilization in clinical practice in China, which could help address this gap. Objectives: To understand utilization of LAI and to assess the impact of switching from oral to LAI antipsychotics on adherence and healthcare utilization. Design: This is a retrospective, 1-year mirror-image study using electronic health records (2012-2019) from a psychiatric specialized hospital and the psychiatry department in a general hospital in China. The observation period was 1 year before and after LAI initiation in patients already receiving oral antipsychotics. Methods: Adult patients (aged 18-65) who initiated LAIs after receiving oral antipsychotics, with schizophrenia diagnosis at least 12 months before LAI initiation were included. The date of LAI initiation was designated as the index date. Adherence to antipsychotics was assessed by the proportion of days covered. Schizophrenia-related healthcare utilization comprised the percentage of patients who had admissions, the duration of inpatient stays, the number of inpatient visits, and outpatient visits. Wilcoxon signed-rank test and McNemar's test were used for before-after comparison. Results: Overall, 98 and 59 eligible patients were included in two hospitals, respectively. Treatment adherence (proportion of days covered) after switching increased significantly from 46% to 61% ( Conclusion: Consistent benefits of LAIs in enhancing treatment adherence and optimizing healthcare utilization were observed in two representative hospitals having different clinical settings and patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.